Phase 3 with Novel B Cell Activating Monoclonal Antibody to Treat COVID-19

PI: Lior Nesher. Funded: PPD

A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

PI: Lior Nesher